Anavex Life Sciences Corp (AVXL)

[falconer66a]

Spilled beans not on the investor’s menu.

Wondering when Anavex will spill the beans (data) - regarding the intermittent dosing as a means to validate the patent.

Well, that’s not going to happen. “Spilled beans” data are presumed to be corrupted, by the dirt on the lab floor where the spilled beans landed.

I marvel (but understand) the frustrating posts castigating Anavex CEO Christopher Missling for “failing to release new data.”

But, the fact is, most “new data,” in investor information webinars, or in detailed corporate announcements, just don’t move the AVXL share price needle. Most potential new AVXL share buyers are interested in but one thing: Will Anavex start to make money from any of its candidate new drugs?

Fact is, corporate revenues, driving high share prices, don’t come from spilled beans of any sort. Anavex could announce that their drug, blarcamesine, safely and effectively treats Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s --- and the share price will be unaffected. In fact, on the Anavex website there is an abundance of well-cooked clinical-result beans, un-spilled, un-spoiled, showing that blarcamesine does work. Most stock investors are paying no attention. They want to see that revenues will be coming to the company. They know that will happen only after the drug gets approval to be sold as a prescription therapy.

Forget the beans, no matter how good the recipe is. Hungry as we all are for tasty Anavex beans, we must wait for the main meal: regulatory approval of blarcamesine. Patience....